Investing Port

P/BV	10.57
EV/EBITDA	-47.95
EBITDA	-0.08
Цена ао	44.1

Institutions	Объем	Доля, %
RTW INVESTMENTS, LLC	7510412	7.67
Ghost Tree Capital, LLC	525000	0.54
Defiance ETFs, LLC	26689	0.03
Invesco Capital Management LLC	394325	0.4
Longwood Capital Partners LLC	250000	0.26
Heptagon Capital Limited	199840	0.2
Bvf Inc	1198427	1.22
Cormorant Asset Management, LLC	1637951	1.67
AlphaCentric Advisors LLC	2150	0
Vivo Capital, LLC	1042460	1.06
Driehaus Capital Management (USVI) LLC	86639	0.09
Parkman Healthcare Partners LLC	150151	0.15
Putnam	225600	0.23
Putnam Investment Management, LLC	118465	0.12
PURA VIDA INVESTMENTS, LLC	270806	0.28
Boston Management and Research	58428	0.06
Principal Global Investors, LLC	134438	0.14
Ikarian Capital, LLC	321887	0.33
Camber Capital Management LLC	438800	0.45
ALPS Advisors Inc	157400	0.16
Pinz Capital Management, LP	199100	0.2
Prudential Retirement Services	65324	0.07
Mangrove Partners	230307	0.24
BlackRock Fund Advisors	2147508	2.19

ETF	Доля, %	Доходность за год, %
ALPS Medical Breakthroughs ETF	2.47	35.77
Defiance Next Gen SPAC Derived ETF	1.64

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.